Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 14,346 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Digestive System Clear all
Completed Phase 2 Interventional Results available

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

NCT01516216
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFOX + bevacizumab, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
18
States / cities
Boise, Idaho • Fruitland, Idaho • Meridian, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer

NCT00002506
View directory record Official record
Conditions
Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions
recombinant interferon alfa, isotretinoin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
6
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 30, 2026, 9:11 AM EDT
Terminated Phase 4 Interventional Results available

Haloperidol vs Conventional Therapy for Gastroparesis

NCT02057549
View directory record Official record
Conditions
Gastroparesis
Interventions
Haloperidol, Conventional Therapy
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Localized Therapeutics for the Treatment of Gastrointestinal Disorders II

NCT02745678
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Thermosensitive gel rectal formulation
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Not applicable Interventional

Functional Outcomes in Ulcerative Colitis Patients With Ileal Pouch Anal Anastomosis Treated With High Intensity Focused Electromagnetic Stimulation

NCT07034443
View directory record Official record
Conditions
Fecal Incontinence
Interventions
High Intensity Focused Electromagnetic Stimulation
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Active, not recruiting Not applicable Interventional

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

NCT02514525
View directory record Official record
Conditions
Barrett Esophagus
Interventions
CryoBalloon Ablation System
Device
Lead sponsor
Pentax Medical
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Orange, California • Sarasota, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, radiofrequency ablation
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Sep 30, 2026, 9:11 AM EDT
Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions
MRTX1133
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Withdrawn Phase 4 Interventional

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy

NCT01386255
View directory record Official record
Conditions
Cerebral Palsy, GERD
Interventions
Baclofen, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643
View directory record Official record
Conditions
Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
Interventions
LY2523355, pegfilgrastim
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Jacksonville, Florida • Macon, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational Results available

Axonics SacRal NeuromodulaTIon System RegisTRY Study

NCT05064384
View directory record Official record
Conditions
Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
Interventions
Not listed
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • Irvine, California • Redwood City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

NCT03221426
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia

NCT00043043
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 30, 2026, 9:11 AM EDT
Active, not recruiting Phase 3 Interventional

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
3 Months to 45 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LB-P8 low-dose, LB-P8 high-dose, Placebo
Drug
Lead sponsor
LISCure Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

NCT01213043
View directory record Official record
Conditions
Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
Interventions
Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions
MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Drug · Combination Product
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 1Phase 2 Interventional

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

NCT00120835
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, pegylated interferon
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Timeline
Started 2004
U.S. locations
2
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting No phase listed Observational

Lucid Registry Study

NCT05965999
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Interventions
EsoCheck®, EsoGuard®
Device · Diagnostic Test
Lead sponsor
Lucid Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lake Forest, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer

NCT01986738
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Standard Radiation Therapy, Active Breathing Control Device (ABC), Computed Tomography Scan (CT)
Radiation · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

NCT02461758
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Standard dose Influenza vaccine (SDIV), High dose influenza vaccine (HDIV)
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 30, 2026, 9:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

NCT05660278
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 30, 2026, 9:11 AM EDT